Form 4: Pacific Biosciences CEO Acquires Shares and Stock Options
SEC Form 4 Filing
Christian O. Henry, CEO of Pacific Biosciences, reports acquisition of shares and stock options.
Summary
- Christian O. Henry, the President, CEO & Interim CFO of Pacific Biosciences, filed a Form 4 detailing changes in beneficial ownership.
- On March 19, 2025, Henry acquired 920,810 shares of Common Stock represented by Restricted Stock Units (RSUs) at a price of $0.
- These RSUs will vest in equal annual installments on February 15 of 2026 and 2027, contingent upon continued service.
- Henry also acquired options to purchase 1,841,621 shares of Common Stock at an exercise price of $1.25 on March 19, 2025.
- These options will vest in 24 equal monthly installments starting March 15, 2025, also subject to continued service.
- Following these transactions, Henry directly owns 3,146,167 shares of Common Stock and 1,841,621 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive. The CEO increasing their stake in the company is generally a good sign, suggesting confidence in the company's future. However, it's a routine filing and doesn't necessarily indicate a major shift in the company's prospects.
Positives
- The CEO's acquisition of shares and options could be interpreted as a positive signal, indicating confidence in the company's future performance.
- The vesting schedules for both the RSUs and stock options incentivize the CEO to remain with the company for the long term.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Comparison to Industry Standards
- Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
- The vesting schedules described are typical for such grants, incentivizing long-term commitment.
- Comparing the size of the grant to those of executives at peer companies like Illumina or Thermo Fisher Scientific would provide further context.
Stakeholder Impact
- Shareholders may view the CEO's increased ownership as a positive sign.
- Employees may be encouraged by the CEO's commitment to the company.
Key Dates
| Date | Description |
|---|---|
| 03/15/2025 | Options vest in 24 equal monthly installments beginning on this date. |
| 03/19/2025 | Date of transaction for shares and stock options. |
| 03/21/2025 | Date of signature on the Form 4 filing. |
| 02/15/2026 | First annual installment vesting date for RSUs. |
| 02/15/2027 | Second annual installment vesting date for RSUs. |
| 03/19/2035 | Expiration date for the stock options. |
Keywords
Pacific Biosciences, PACB, Christian O. Henry, Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, RSUs, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.